Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 3, 2011, Pages 644-654

  Beltran, Pedro J ^a   Chung, Young Ah ^a   Moody, Gordon ^a   Mitchell, Petia ^a   Cajulis, Elaina ^a   Vonderfecht, Steven ^a   Kendall, Richard ^a   Radinsky, Robert ^a   Calzone, Frank J ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GANITUMAB; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; EWING SARCOMA; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOSARCOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, NUDE; OSTEOSARCOMA; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SARCOMA, EWING'S; SIGNAL TRANSDUCTION; SIROLIMUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956205779     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.178400     Document Type: Article

References (37)

1. Arvand A and Denny CT (2001) Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20:5747-5754. (Pubitemid 32928112)
2. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, et al. (2009) Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 69:2443-2452.
3. Belfiore A, Frasca F, Pandini G, Sciacca L, and Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586-623.
4. Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, et al. (2009) AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 8:1095-1105.
5. Bjornsti MA and Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-348.
6. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, and Lane HA (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 8:742-753.
7. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, et al. (2010) Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 9:2652-2664.
8. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, Khanna C, and Helman LJ (2008) Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 68:8039-8048.
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954. (Pubitemid 34716871)
10. Heare T, Hensley MA, and Dell'Orfano S (2009) Bone tumors: osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr21:365-372.
11. Hughes DP (2009) Novel agents in development for pediatric sarcomas. Curr Opin Oncol 21:332-337.
12. Iwamoto Y (2007) Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol 37:79-89.
13. Kim SY, Toretsky JA, Scher D, and Helman LJ (2009) The role of IGF-1R in pediatric malignancies. Oncologist 14:83-91.
14. Kurmasheva RT, Huang S, and Houghton PJ (2006) Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 95:955-960. (Pubitemid 44606818)
15. Longhi A, Errani C, De Paolis M, Mercuri M, and Bacci G (2006) Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32:423-436. (Pubitemid 44309249)
16. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, and Singh R (2003) An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073-5083. (Pubitemid 37022647)
17. Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C, Hofmann F, García-Echeverría C, Picci P, et al. (2007) Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 13:1322-1330. (Pubitemid 46424074)
18. Mateo-Lozano S, Gokhale PC, Soldatenkov VA, Dritschilo A, Tirado OM, and Notario V (2006) Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clin Cancer Res 12:6781-6790. (Pubitemid 44876848)
19. Mateo-Lozano S, Tirado OM, and Notario V (2003) Rapamycin induces the fusiontype independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 22:9282-9287. (Pubitemid 38122040)
20. Meric-Bernstam F and Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27:2278-2287.
21. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, et al. (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5:221-230. (Pubitemid 38402114)
22. Nawijn MC, Alendar A, and Berns A (2011) For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 11:23-34.
23. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508. (Pubitemid 43259931)
24. Oliner JD, Kinzler KW, Meltzer PS, George DL, and Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83.
25. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928.
26. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, et al. (2006) AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66:8715-8721. (Pubitemid 44449188)
27. Prieur A, Tirode F, Cohen P, and Delattre O (2004) EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24:7275-7283. (Pubitemid 39014452)
28. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, and van der Graaf WT (2009) The insulin-like growth factor system and sarcomas. J Pathol 217:469-482.
29. Rodon J, DeSantos V, Ferry RJ Jr, and Kurzrock R (2008) Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7:2575-2588.
30. Scotlandi K and Picci P (2008) Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 20:419-427.
31. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, and Lessnick SL (2006) Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 9:405-416. (Pubitemid 43668735)
32. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, and Khuri FR (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65:7052-7058. (Pubitemid 41161231)
33. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, et al. (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27:5800-5807.
34. Wan X, Harkavy B, Shen N, Grohar P, and Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26:1932-1940. (Pubitemid 46474636)
35. Wan X and Helman LJ (2007) The biology behind mTOR inhibition in sarcoma. Oncologist 12:1007-1018. (Pubitemid 47359144)
36. Wang X, Hawk N, Yue P, Kauh J, Ramalingam SS, Fu H, Khuri FR, and Sun SY (2008a) Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther 7:1952-1958.
37. Wang X, Yue P, Kim YA, Fu H, Khuri FR, and Sun SY (2008b) Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 68:7409-7418.